These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 447039)

  • 1. The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites.
    Blendis LM; Greig PD; Langer B; Baigrie RS; Ruse J; Taylor BR
    Gastroenterology; 1979 Aug; 77(2):250-7. PubMed ID: 447039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and hemodynamic effects of the peritoneovenous shunt. II. Long-term effects.
    Greig PD; Blendis LM; Langer B; Taylor BR; Colapinto RF
    Gastroenterology; 1981 Jan; 80(1):119-25. PubMed ID: 7004991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyponatremia and arginine vasopressin secretion in patients with refractory hepatic ascites undergoing peritoneovenous shunting.
    Reznick RK; Langer B; Taylor BR; Seif S; Blendis LM
    Gastroenterology; 1983 Apr; 84(4):713-8. PubMed ID: 6337910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
    La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
    Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of peritoneovenous shunting in unravelling the pathogenesis of ascites in cirrhosis.
    Blendis LM
    Isr J Med Sci; 1986 Feb; 22(2):78-80. PubMed ID: 3512475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acute effects of sustained volume expansion on the renin-aldosterone system and renal function in human hepatic ascites.
    Greig PD; Blendis LM; Langer B; Ruse J; Taylor BR
    J Lab Clin Med; 1981 Jul; 98(1):127-34. PubMed ID: 7019366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites.
    Orloff MJ; Orloff MS; Orloff SL; Girard B
    J Am Coll Surg; 1997 Jun; 184(6):557-70. PubMed ID: 9179111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.
    Somberg KA; Lake JR; Tomlanovich SJ; LaBerge JM; Feldstein V; Bass NM
    Hepatology; 1995 Mar; 21(3):709-16. PubMed ID: 7875668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
    Wong W; Liu P; Blendis L; Wong F
    Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.
    Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM
    Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved renal function and inhibition of renin and aldosterone secretion following peritoneovenous (LeVeen) shunt.
    Berkowitz HD; Mullen JL; Miller LD; Rosato EF
    Surgery; 1978 Jul; 84(1):120-6. PubMed ID: 663820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aldosterone and renin in liver cirrhosis with ascites].
    Vetter H; Vetter W; Beckerhoff R; Glänzer K; Furrer J; Hahn C; Kolloch R; Krück F; Kutz K; Siegenthaler W; Witassek F
    Schweiz Med Wochenschr; 1977 Dec; 107(48):1755-9. PubMed ID: 929137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems.
    Saló J; Guevara M; Fernández-Esparrach G; Bataller R; Ginès A; Jimenez W; Ginès P; Rivera F; Arroyo V; Rodés J
    Hepatology; 1997 Jun; 25(6):1338-42. PubMed ID: 9185749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.
    Quiroga J; Sangro B; Núñez M; Bilbao I; Longo J; García-Villarreal L; Zozaya JM; Betés M; Herrero JI; Prieto J
    Hepatology; 1995 Apr; 21(4):986-94. PubMed ID: 7705810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation.
    Wong F; Tobe S; Legault L; Logan AG; Skorecki K; Blendis LM
    Hepatology; 1993 Sep; 18(3):519-28. PubMed ID: 8395457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.
    Gerbes AL; Gülberg V; Waggershauser T; Holl J; Reiser M
    Hepatology; 1998 Sep; 28(3):683-8. PubMed ID: 9731559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.